肝移植术后乙型肝炎病毒再激活的分子机制研究进展  

Research progress on molecular mechanism of hepatitis B virus reactivation after liver transplantation

作　　者：杨健[1] 谢炎 田大治[1] 张骊[1] 张洋铭 蒋文涛[1] Yang Jian;Xie Yan;Tian Dazhi;Zhang Li;Zhang Yangming;Jiang Wentao(Organ Transplantation Center,Department of Organ Transplantation,Tianjin First Central Hospital,Tianjin 300192,China)

机构地区：[1]天津市第一中心医院器官移植中心器官移植科,300192

出　　处：《器官移植》2020年第2期298-303,共6页Organ Transplantation

基　　金：国家自然科学基金面上项目(81870444);天津市科委慢性病防治科技重大专项(17ZXMFSY00040);天津市第一中心医院春蕾计划(CL201801);天津市自然科学基金(19JCQNJC10300)。

摘　　要：肝移植是治疗乙型病毒性肝炎(乙肝)相关性肝衰竭、肝硬化和肝细胞癌(肝癌)的最有效方法。然而,肝移植术后乙型肝炎病毒(HBV)再激活不利于移植肝功能恢复且导致预后不良,其防治问题是当前内、外科医师研究的焦点。目前的病毒抑制策略不能完全根除HBV,也不能完全预防HBV在未来复发感染。本文旨在探讨肝移植术后HBV再激活的分子机制,以期更有效预防肝移植术后乙肝复发。Liver transplantation is the most effective method for hepatitis B-related liver failure,liver cirrhosis and hepatocellular carcinoma.However,the reactivation of hepatitis B virus(HBV)after liver transplantation is not conducive to the recovery of liver function and leads to poor clinical prognosis.The prevention and treatment of HBV reactivation is currently the focus of research by physicians and surgeons.The current viral suppression strategies can not completely eradicate HBV nor completely prevent the recurrence of HBV infection in the future.This article aims to explore the molecular mechanism of HBV reactivation after liver transplantation,in order to more effectively prevent the recurrence of hepatitis B after liver transplantation.

关 键 词：肝移植 乙型肝炎病毒 超螺旋共价闭环DNA(cccDNA) 基因整合 肝外复制 乙型病毒性肝炎复发 丁型肝炎病毒 基因型 

分 类 号：R617[医药卫生—外科学] R373.21[医药卫生—临床医学]